Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Constellation Brands to Report Third Quarter Fiscal 2024 Financial Results; Host Conference Call January 5, 2024 1-12-2023, 04:30

Corbion launches AlgaPrime™ DHA P3, addressing the demand for sustainable active nutrition in the pet food industry 26-09-2023, 05:15